180 related articles for article (PubMed ID: 10652575)
21. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
22. Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma.
Morell-Quadreny L; Rubio J; Lopez-Guerrero JA; Casanova J; Ramos D; Iborra I; Solsona E; Llombart-Bosch A
Anticancer Res; 2003; 23(6D):5005-10. PubMed ID: 14981959
[TBL] [Abstract][Full Text] [Related]
23. Morphological aspects of altered basement membrane metabolism in invasive carcinomas of the breast and the larynx.
Nerlich AG; Lebeau A; Hagedorn HG; Sauer U; Schleicher ED
Anticancer Res; 1998; 18(5A):3515-20. PubMed ID: 9858933
[TBL] [Abstract][Full Text] [Related]
24. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.
Pyke C; Ralfkiaer E; Huhtala P; Hurskainen T; Danø K; Tryggvason K
Cancer Res; 1992 Mar; 52(5):1336-41. PubMed ID: 1310643
[TBL] [Abstract][Full Text] [Related]
25. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
Chu CY; Cha ST; Chang CC; Hsiao CH; Tan CT; Lu YC; Jee SH; Kuo ML
Oncogene; 2007 Apr; 26(17):2491-501. PubMed ID: 17099730
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinase-13 and Ki-67 in nonmelanoma skin cancer in xeroderma pigmentosum and non-xeroderma pigmentosum.
El-Hawary AK; Yassin E; Khater A; Abdelgaber S
Am J Dermatopathol; 2013 Feb; 35(1):45-9. PubMed ID: 22722466
[TBL] [Abstract][Full Text] [Related]
27. [Distribution and expression of basement membrane proteins in malignant eyelid tumors and its clinical significance].
Lin H; Niu YJ; Zhou ZY; Liu FL; Wang HY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):167-71. PubMed ID: 12880575
[TBL] [Abstract][Full Text] [Related]
28. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication.
Yu W; Liu J; Xiong X; Ai Y; Wang H
Pathol Res Pract; 2009; 205(10):709-15. PubMed ID: 19541433
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of TIMP-3 and MMP-9 in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma.
Poswar FO; Fraga CA; Farias LC; Feltenberger JD; Cruz VP; Santos SH; Silveira CM; de Paula AM; Guimarães AL
Pathol Res Pract; 2013 Nov; 209(11):705-9. PubMed ID: 24011615
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of MMP-2 and MMP-9 in squamous cell carcinomas of immunosuppressed patients.
Chebassier N; Leroy S; Tenaud I; Knol AC; Dreno B
Arch Dermatol Res; 2002 May; 294(3):124-6. PubMed ID: 12029498
[No Abstract] [Full Text] [Related]
31. Expression of MMP-2, -9 and -13 in cell lines and fresh biopsies of squamous cell carcinomas of the upper aerodigestive tract.
Dünne AA; Sesterhenn A; Gerisch A; Teymoortash A; Kuropkat C; Werner JA
Anticancer Res; 2003; 23(3B):2233-9. PubMed ID: 12894497
[TBL] [Abstract][Full Text] [Related]
32. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.
Ala-aho R; Grénman R; Seth P; Kähäri VM
Oncogene; 2002 Feb; 21(8):1187-95. PubMed ID: 11850838
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
34. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression.
Iovieno A; Lambiase A; Moretti C; Perrella E; Bonini S
Cornea; 2009 Aug; 28(7):821-4. PubMed ID: 19574900
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases 2 and 9, and extracellular matrix in Kaposi's sarcoma.
Bongiorno MR; Doukaki S; Ferro G; Aricò M
Dermatol Ther; 2010; 23 Suppl 2():S33-6. PubMed ID: 20482566
[TBL] [Abstract][Full Text] [Related]
39. Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
Ramachandran S; Rajaratnam R; Smith AG; Lear JT; Strange RC
J Am Acad Dermatol; 2009 Aug; 61(2):247-51. PubMed ID: 19481292
[TBL] [Abstract][Full Text] [Related]
40. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
Zhang G; Luo X; Sumithran E; Pua VS; Barnetson RS; Halliday GM; Khachigian LM
Oncogene; 2006 Nov; 25(55):7260-6. PubMed ID: 16785994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
